YAKHAK HOEJI (약학회지)

The Pharmaceutical Society of Korea (대한약학회)
권호 표지

Comparison of Efficacy Between Micronised- and Non-micronised Fenofibrate in Type 2 Diabetic Patients with Dyslipidemia

이상지혈증을 동반한 제2형 당뇨병환자에서 미세화된 fenofibrate

  • 신화연 (숙명여자대학교 임상약학대학원) ;
  • 오정미 (숙명여자대학교 임상약학대학원) ;
  • 강문호 (가천의과대학교 길병원 내분비내과) ;
  • 신현택 (숙명여자대학교 약학대학)
  • Published : 2001.10.01
Download PDF
⟨ Previous Next ⟩

Abstract

Fenofibrate is a fibric acid derivative that is a strong reducer of triglyceride. Micronozed formulation of fenofibrate has improved bioavailability compared to non-micrornized formulation. This study performed a retrospective comparison of micrornized and non-micrornized fenofibrate (28 in micronized and 51 in non-micronized group) by comparing the means of changes in total triglyceride, total cholesterol, HDL-cholesterol and TC/HDL ratio in type 2 diabetics with dyslipidemia The result skewed that after 12 weeks of treatment both drugs produced a significant reduction in total triglyceride levels (62% with micronized, 37% with non-micronized). The mean decrease observed for total triglyceride levels were significantly lower for micronized fenofibrate (p<0.001). Both drugs showed a significant reduction for total cholesterol levels (-22% with micronized, -14% with non-micronized fenofibrate). The mean decrease observed for total cholesterol was not significantly different between the two drugs (p>0.05). HDL-cholesterol levels increased by 24% and 15%) with micronized and non-micronized, respectively and the differences from the baseline were statistically significant for both drugs (p<0.05). The mean change of HDL-cholesterol was not significantly different between the two drugs. There was a statistically significant reduction in TC/HBL-cholesterol ratio from baseline for both drugs (7.1 to 4.8 with micronized and 5.1 to 4.5 with non-micronized), and the reduction of TC/HDL-cholesterol ratio tended to be significantly greater with micronized fenofibrate (p<0.05). This study shows that short-term treatment with micronized fenofibrate is more effective than non-micronized fenosbrate in type 2 diabetes patients with dyslipidemia.

Keywords

References

  1. Med.J.Aust.Dec. v.159 no.11-12 The Diabetes Control and Complications Trial(DCCT).A milestone in diabetes management Chrisholm,D.J.
  2. Grop.Lancet. v.12 no.352(9131) Intensive bleed-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type2 diabetes(UKPDS33).UK Prospective Diabetes Stedy(UKPDS)
  3. Diabetes Res.Clin.Pract. v.28 no.103 Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin dependent diabetes melitus Ohkuba,Y.;Kishikawa,H.;Araki,E.
  4. Am.J.Med. v.96 no.25S Diabetic dyslipidemia Betteridge,D.J.
  5. Diabetes Metab.Rev. v.10 no.225 Insulin and lipoprotein metabolism with special reference to the diabetic state Tomkin,G.H.;Owens,D.
  6. Endocrine Rev. v.15 no.263 Dyslipidemia in non-insulin-dependent diabetes melitus Howard,B.V.;Howard,W.J.
  7. Diabetes Rev. v.3 no.408 Epidemiology of diabetic dyslipidemia Laakso,M.
  8. Diabetes v.31 no.126 Abnormal concentration of high density lipoprotein in non-insulin-dependent diabetics Biesbroeck,R.C.;Albers,J.J.;Wahl,P.W.;Weinberg,C.R.;Basett,M.L.;Bierman,E.L.
  9. Am.J.Epiemiol. v.115 no.657 Plasma lipids and diabetes mellitus in an adult community Barret-Connor,E.;Grundy,S.M.;Holbrook,M.J.
  10. Diabetes Care. v.16 no.434 Risk factors and 12-yrcardiovascular mortality for men screened in the multiple risk factor intervention trial Unsitupa,M.;Siitonen,O.;Voutilainen,E.;Aro,A.;Hersioo,K.;Pyorala,K.
  11. Diabetes v.34 no.8 Meta-bolism of LDL from patients with diabetic hypergly-ceridemia by cultured human skin fibroblasts Hiramatzu,K.;Bierman,E.L.;Chait,A.
  12. Arch.Intern.Med. v.130 no.833 Atherosclerosis in diabetes mellitus.Correlations with serum lipid levels,adiposity and serum insulin level. Santon,R.J.;Willis,P.W.;Fanjas,S.S.
  13. Diabetologia v.32 no.300 Hypertrigly-ceridemia as a risk factor of coronary heart disease mortality in subjects with impaired glucose tolerance or diabetes:results from the 11-year fallow-up of the Paris Prospective Study. Fontbonne,A.;Eschwege,E.;Cambien,F.;Richard,J.L.;Ducimetiere,P.;Thibult,N.
  14. Br.Med.J. v.1 no.883 High density and low density lipoproteins and prevalence of vascular.Disease in diabetes mellitus Reckless,J.P.D.;Betteridge,D.J.;Wu,P.;Payne,B.;Galton,D.J.
  15. Diabetologia v.27 no.568 Clinical macrovascular disease in diabetic subjects:logistic regression analysis of risk variables Welborn,T.A.;Knuiman,M.;McCann,V.;Stanton,K.;Constable,I.J.
  16. Curr.Opin.Lipidol. v.6 no.360 Selection of appropriate type and intensity of lipid-lowering therapy Tikkanen,M.J.
  17. Diabetes Care. v.21 no.S36 Management of dyslipidemia in adults with diabetes American Diabetes Association
  18. Am.J.Cardiol. v.66 no.16B Comparison of the effects of lovastatin and Gemfibrozil on lipids and glucose control in non-insulin dependent diabetes mellitus Goldberg,R.;La Belle,P.;Zupkis,R.;Ronca,P.
  19. J.Clin.Endocrinol.Metab. v.73 no.503 Effect of gemfibrozil treatment in sulfonylurea-treated patients with non-insulin-dependent diabetes mellitus Shen,D.C.;Fuh,M.M.T.;Shieh,S.M.;Chen,Y.D.;Reaven,G.M.
  20. J.Clin.Endocrinol.Metab. v.73 no.503 Effect of gemfibrozil treatment in sulfonylurea-treated patients with non-insulin-dependent diabetes mellitus Shen,D.C.;Fuh,M.M.T.;Shieh,S.M.;Chen,Y.D.;Reaven,G.M.
  21. Atherosclerosis v.101 no.79 Effect of gemfibrozil on high density lipoprotein subspecies in non-insulin dependent diabetes mellitus.Relations to lipolytic enzymes and to the cholesterol ester transfer protein activity Kahri,J.;Vuorine-Markkola,H.;Tilly-Kiesi,M.;Lahdenpera,S.;Taskinen,M.R.
  22. Diabetes Care. v.16 no.584 Effects of gemfibrozil on low-density lipoprotein particle size,density distribution and composition in patients with type Ⅱdiabetes Lahdenpera,S.;Tilly-Kiesi,M.;Vuorinen-Markkola,M.;Kuusi,T.;Tskinen,M.R.
  23. JAMA. v.231 no.360 clofibrate and niacin in coronary heart disease The Coronary Drug Project Research Group
  24. Atheroclerosis. v.38 no.273 Fenofibrate therapy of hyperlipoproteinemia:a dose-response study and a comparison with clofibrate Rossner,S.;Oro,L.
  25. Metabolism v.37 no.217 Hypertriglyceridemia and hyperuricemia:effects of two fibric acid derivative and fenofibrate in a doubleblind,placebo-controlled tral Bastow,M.D.;Durrinaton,P.N.;Ishola,M.
  26. Am.J.Med. v.83 no.3 Structure and biochemical effects of fenofibrate Kloer,H.U.
  27. Am.J.Med. v.83 no.3 Structure and biochemical effects of fenofibrate Kloer,H.U.
  28. Thromb.Hamostasis v.70 no.2 Effect of theree fibrate derivatives and of two HMG-CoA reductase inhibitors on plasma fibrinogen level in patients with primary hypercholesterolemia Branchi,A.;Rovellini,A.;Sommariva,D.
  29. Curr.Ther.Res. v.47 no.952 Fenofibrate and reduction of coronary heart disease Edgar,A.D.
  30. Drugs. v.54 no.615 Micronised fenofibrate:a review of its pharmacodynamic properties and clinical efficacy in the management of dyslipidaemia Adkins,J.C.;Faulds,D.
  31. Curr.Ther.Res. v.54 no.610 A comparison of the bioavailability of standard or micronized formulation of fenofibrate Guichard JP;Sauron RLP
  32. Product Information Tricor(TM),micornized fenofibrate capsules
  33. Diabetes Metab.Rev. v.13 no.93 Triglyceride is the major aterogenic lipid in NIDDM. Taskinen,M.R.
  34. Diabetologia. v.32 no.300 Hypertrigly-ceridaemia as a risk factor of coronary heart disease mortality in subjects with impaired glucose tolerance or diabetes Fontbonne,A.;Eschwege,E.;Cambien,F.;Richard,J.L.;Ducimetier,P.;Thibult,N.